Table 1.
A list of FDA-approved nanoparticle drug delivery systems in clinical trials and/or in use [2]
| Therapeutic agent (trade name) | Indication |
|---|---|
| Liposomal amphotericin B (Ambisome, Ablecet, Amphotec) | Fungal infections, Leishmaniasis |
| PEG-adenosine deaminase (Pegadamase) | Severe combined immunodeficiency disease |
| PEG-stabilized liposomal doxorubicin (Doxil, Evacet) | Kaposi’s sarcoma, refractory ovarian cancer |
| Liposomal cytosine arabinoside (DepoCyt) | Lymphomatous meningitis, neoplastic meningitis |
| Interleukin 2-diptheria toxin fusion protein (Deniliekin, Diffitox) | Cutaneous T-cell lymphoma |
| Liposomal verteporfin (Visudyne) | Wet macular degeneration |
| PEG-interferon α-2b (Pegasys) | Hepatitis C |
| PEG-granulocyte colony stimulating factor (Neulasta) | Chemotherapy associated neutropenia |
| Protein bound paclitaxel (Abraxane) | Metastatic breast cancer |
| PEG L-asparaginase (Oncaspar) | Acute lymphocytic leukemia |
| PEG aptanib (Macugen) | Wet macular degeneration |
| Pemetrexid (Alimta) | Malignant pleural mesothelolioma |